Articles

May 2, 2014 — Medtronic Inc. revealed new data demonstrating positive outcomes for extreme risk patients with severe aortic stenosis who were treated with the CoreValve system via alternative...

May 2, 2014 — Terso Solutions Inc., a provider of automated inventory management solutions for healthcare and life science, announced that Endologix Inc. has partnered with them for a fully...

Volcano Corp. announced the commencement of its limited market release of its U.S. Food and Drug Administration (FDA) cleared and CE marked technology SyncVision, with cases being performed in the...

FDA Clearnace Volcano Corp. iFR Modality FFR Catheter Cath Lab

Volcano Corp. announced U.S. Food and Drug Administration (FDA) clearance of its proprietary Instant Wave-Free Ratio (iFR) modality.

April 16, 2014 — Abbott announced it has completed enrollment of three clinical trials to support approvals of the company's Absorb bioresorbable vascular scaffold (BVS) in the United States,...

Corevalve beats surgery, ACC 2014, TAVR vs surgery, Edwards lawsuit

The U.S. District Court for the District of Delaware granted a preliminary injunction limiting the sale of Medtronic's CoreValve transcatheter aortic valve replacement (TAVR) system in the United...

SCAI ACC.14 Choosing Wisely Campaign Tests Treatments to Avoid Cath Lab

The Society for Cardiovascular Angiography & Interventions (SCAI) issued a list of five specific, evidence-based recommendations that should be avoided in the care of patients who have, or are...

Merge, CVIS, cardiac PACS

Patients do not have to be the only beneficiaries of technological innovation. Indeed, many technological hardware and software solutions are emerging to help cardiac care providers negotiate...

In a comparison of two blood-thinning medications, heparin was associated with significantly fewer major cardiovascular events at 28 days than bivalirudin in patients receiving primary...

Medtronic, SYMPLICITY, SYMPLICITY HTN-3 trial, renal denervation, ACC.14

A major disappointment earlier this year was the announcement by Medtronic that its renal denervation system failed to meet its primary endpoint for efficacy in the U.S. SYMPLICITY HTN-3 trial....